News Releases


2016 | 2015 | 2014 | Archive
Keyword Search
 
DateTitle 
05/05/16ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results
SAN DIEGO--(BUSINESS WIRE)--May 5, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2016. “We are very excited about the recent FDA approval of NUPLAZID™, the first and only drug approve... 
Printer Friendly Version
05/04/16ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 11, 2016
SAN DIEGO--(BUSINESS WIRE)--May 4, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 11, 2016, at 2:20 p.m. Pacific Time in Las Vegas. A live webcast of ACA... 
Printer Friendly Version
05/02/16ACADIA Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 5, 2016
ACADIA to Host Conference Call and Webcast on Thursday, May 5, 2016, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--May 2, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its unaudited financial results for the first quart... 
Printer Friendly Version
04/29/16FDA Approves ACADIA Pharmaceuticals’ NUPLAZID™ (pimavanserin) - The First Drug Approved for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
U.S. Commercial Launch Planned for June 2016 An Estimated 40 Percent of Parkinson’s Disease Patients Have Psychosis Conference Call Scheduled on Monday, May 2 at 8:30 a.m. ET SAN DIEGO--(BUSINESS WIRE)--Apr. 29, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) ... 
Printer Friendly Version
04/06/16ACADIA Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference on April 12, 2016
SAN DIEGO--(BUSINESS WIRE)--Apr. 6, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016, at 8:40 a.m. Eastern Time in New York City. A live webcast of ACADIA’s ... 
Printer Friendly Version
03/29/16FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID™ (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks
SAN DIEGO--(BUSINESS WIRE)--Mar. 29, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 12 to 2 that the benefits of NUPLAZID™ (pimavanserin) for the treatment ... 
Printer Friendly Version
03/29/16ACADIA Pharmaceuticals Stock Trading Halted Today
FDA Advisory Committee to Review NUPLAZID™ (Pimavanserin) New Drug Application for the Treatment of Parkinson’s Disease Psychosis SAN DIEGO--(BUSINESS WIRE)--Mar. 29, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that NASDAQ has halted trading of the ... 
Printer Friendly Version
03/01/16ACADIA Pharmaceuticals to Present at the Cowen and Company 36th Annual Health Care Conference on March 8, 2016
SAN DIEGO--(BUSINESS WIRE)--Mar. 1, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8, 2016, at 8:40 a.m. Eastern Time in Boston. A live webcast of ACADIA... 
Printer Friendly Version
02/29/16ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015
SAN DIEGO--(BUSINESS WIRE)--Feb. 29, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the fourth quarter and year ended December 31, 2015. “2015 was highlighted by the filing of our NUPLAZID™ (pimavanserin) New Drug Application fo... 
Printer Friendly Version
02/23/16ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016
ACADIA to Host Conference Call and Webcast on Monday, February 29, 2016, at 8:00 a.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Feb. 23, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the fourth quarter and year... 
Printer Friendly Version
02/03/16ACADIA Pharmaceuticals to Present at the LEERINK Partners 5th Annual Global Healthcare Conference on February 10, 2016
SAN DIEGO--(BUSINESS WIRE)--Feb. 3, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that it will present at the LEERINK Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016, at 8:00 a.m. Eastern Time in New York City. A live we... 
Printer Friendly Version
01/29/16ACADIA Pharmaceuticals Announces FDA Advisory Committee Meeting to Review NUPLAZID™ (Pimavanserin) for the Treatment of Parkinson’s Disease Psychosis
Advisory Committee Meeting Scheduled for March 29, 2016 SAN DIEGO--(BUSINESS WIRE)--Jan. 29, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that the Psychopharmacologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review ... 
Printer Friendly Version
01/25/16ACADIA Pharmaceuticals Appoints James (Randy) R. Owen, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer
SAN DIEGO--(BUSINESS WIRE)--Jan. 25, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the appointment of James (Randy) R. Owen, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer. Dr. Owen will be responsible for evolving and executing t... 
Printer Friendly Version
01/11/16ACADIA Pharmaceuticals Appoints Jim Daly to Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Jan. 11, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced Jim Daly has joined its Board of Directors. Mr. Daly is a biopharmaceutical executive with 30 years of experience leading U.S. and global businesses. “Jim brings ex... 
Printer Friendly Version
01/07/16ACADIA Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference on January 12, 2016
SAN DIEGO--(BUSINESS WIRE)--Jan. 7, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that it will present at the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016, at 11:30 a.m. Pacific Time in San Francisco. A live webcast of ACAD... 
Printer Friendly Version
01/06/16ACADIA Pharmaceuticals Prices Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)--Jan. 6, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced the pricing of an underwritten public offering of 10,344,827 shares of its common stock, offered at a price to the public of $29.00 per share. The gross proceeds from this offering to AC... 
Printer Friendly Version
01/05/16ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)--Jan. 5, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that it intends to offer and sell, subject to market and other conditions, $300,000,000 of shares of its common stock in an underwritten public offering. There can be no assurance as to ... 
Printer Friendly Version